Clinical Trials Logo

Clinical Trial Summary

Alport syndrome (AS) represents a form of progressive hereditary nephritis in which the genetic defect resides in the synthesis of one of several subunits of type IV collagen, the predominant constituent of basement membranes in renal glomeruli. Renal impairment occurs with time and severe renal failure with hypertension and uremia represent the end stage of the disease, even if a high variability in the rate of progression is described.Males are usually affected by a progressive form of the disease. Affected females with X-linked syndrome usually have a good prognosis with a mild renal impairment. The disease is also associated to a sensor neural deafness which can occur in approximately half of the patient affected and usually correlates with renal impairment. No definite treatment exists in order to delay the time of dialysis or a kidney transplant. Many studies showed that Angiotensin converting enzyme (ACE) inhibitors slow glomerular filtration rate (GFR) decline and limit progression to end stage renal disease (ERDS) and dialysis in several chronic nephropathies associated with proteinuria. The combination of ACE-I with Angiotensin II receptor antagonists may reduce proteinuria more effectively than the two drugs alone. Moreover the addition of statins may synergize the antiproteinuric effects of ACE-I and ATAII antagonists in experimental models of chronic renal diseases. The purpose of this study is to evaluate the effect of a standardized multimodal nephroprotection intervention (Remission Clinic) in Alport patients with renal involvement.


Clinical Trial Description

Alport syndrome (AS) represents a form of progressive hereditary nephritis in which the genetic defect resides in the synthesis of one of several subunits of type IV collagen, the predominant constituent of basement membranes in glomeruli, eye, cochlea. From a genetical point of view, the disease is quite heterogeneous, since we have X-linked, autosomal recessive and autosomal dominant variants of the syndrome. In most cases (about 80%) the model of inheritance is X-linked and the affected patients are males. Here the mutation stays on X-chromosome in a gene codifying for alpha-5(IV). In about 15% of patients the inheritance is autosomal recessive, with a severe disease both in males and females. The involved genes here are located on chromosome 2 and codifying respectively for alpha-3(IV) and alpha-4(IV) chains. In a 5% the model of inheritance is autosomal dominant and here the deterioration of renal function usually occurs more slowly. Clinical manifestations include microscopic hematuria as the first finding, which can also became gross hematuria (episodes during upper respiratory infections) or manifest as intermittent (heterozygous females). Another sign is proteinuria of various degrees. It may be from insignificant, described in heterozygous females, or a progressive proteinuria (recessive or X-linked disease). It is evident from clinical studies of Alport patients that a persistent massive proteinuria, inducing a progressive interstitial fibrosis, indicates a very poor prognosis. The presence of glomerular podocytes has been described in urinary sediments of patients with renal diseases, including AS and recent data suggest that podocyturia could act as a marker for estimating the severity of active glomerular injury and as a predictor of disease progression. Renal impairment occurs with time and severe renal failure with hypertension and uremia represent the end stage of the disease, even if an high variability in the rate of progression is described. The prognosis is variable. Males are usually affected by progressive form of disease. Affected females with X-linked syndrome usually have a good prognosis with a mild renal impairment. Some females evolve in a progressive nephritis. The disease is also associated to a sensorineural deafness which can occur in approximately half of the patient affected and usually correlates with renal impairment. Many studies showed that angiotensin converting enzyme (ACE) inhibitors slow glomerular filtration rate (GFR) decline and limit progression to end stage renal disease (ERDS) and dialysis in several chronic nephropathies. ACE inhibitors delay renal fibrosis both by an hemodynamic mechanism (reduction of the intraglomerular hypertension, glomerular hyperfiltration and associated proteinuria) and a non-hemodynamic mechanism (decrease of angiotensin II, a potent inducer of TGF-β release which is a fibrogenic cytokine). ACE inhibitors given to COL4A3 knockout mouse (a model for autosomal-recessive AS) during pre-symptomatic disease, markedly delayed the onset of proteinuria, progressive renal damage and uremia. Conversely the same treatment did not improve renal outcome in this mouse model if fibrosis and impairment of renal function was already present. These results are in agreement with the findings that ACE inhibitor have beneficial effects against proteinuria, renal function deterioration and survival in Samoyed dogs, a model for X-linked hereditary nephropathy closely mimicking human AS. Moreover recent clinical data suggest that even in young patients affected by AS a decrease in proteinuria and a stabilization in renal function result from the use of ACE inhibition. The combination of ACE-I with ATAII antagonists may reduce proteinuria more effectively than the two drugs alone. Moreover the addition of statins may synergize the antiproteinuric effects of ACE-I and ATAII antagonists in experimental models of chronic renal diseases. Statins given with or without inhibitors of the renin-angiotensin-system have an additive effect on reducing proteinuria also in humans. The purpose of this study is to evaluate the effects of a multimodel treatment including the integrated use of ACE inhibitors (ACE-I), Angiotensin II antagonists (ATA), non dihydropyridinic calcium channel blockers (CCBS) and statins in AS and renal involvement. Aims of the study Primary To evaluate the effect of a standardized multimodal nephroprotection intervention (Remission Clinic) on overnight urine albumin excretion rate (UAE) in Alport patients with renal involvement Secondary 1. To evaluate the effect of the above treatment on: - regression from macro to micro or normoalbuminuria - regression from micro to normoalbuminuria - regression from high-normal albuminuria to low-normal albuminuria - urinary albumin/creatinine ratio - systolic/diastolic blood pressure - urinary podocyte excretion - albumin-IgG-IgM fractional clearances 2. To assess treatment tolerability ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00309257
Study type Interventional
Source Mario Negri Institute for Pharmacological Research
Contact
Status Completed
Phase Phase 2
Start date January 2004
Completion date October 2009

See also
  Status Clinical Trial Phase
Completed NCT01696253 - Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Terminated NCT01602835 - Human Urine Sample Collection for Alport Nephropathy Biomarker Studies N/A
Recruiting NCT00481130 - Alport Syndrome Treatments and Outcomes Registry
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05448755 - A Study of ELX-02 in Patients With Alport Syndrome Phase 2
Recruiting NCT06274489 - A Study to Evaluate Setanaxib in Patients With Alport Syndrome Phase 1/Phase 2
Terminated NCT02855268 - Study of Lademirsen (SAR339375) in Patients With Alport Syndrome Phase 2
Recruiting NCT06226896 - Effects of Dapagliflozin on Progression of Alport Syndrome
Recruiting NCT05927467 - Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Completed NCT03019185 - A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Phase 2/Phase 3
Recruiting NCT06425055 - Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Phase 2
Completed NCT01705132 - Urinary Biomarkers of the Progression of Alport Kidney Disease N/A
Recruiting NCT05267262 - Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Phase 2
Completed NCT00622544 - A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Recruiting NCT02378805 - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Not yet recruiting NCT05655728 - Treatment With Metformin in Chinese Children With Alport Syndrome Phase 4
Not yet recruiting NCT05133050 - Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants N/A
Recruiting NCT04947813 - Genotype-Phenotype Correlations in Patients With Alport Syndrome